AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too

18th May 2026 Uncategorised 0

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British pharma’s goal to strike $80 billion in revenue by the end of the decade.

More: AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
Source: fierce